Supplementary Information

Figures:

A

-NH$_2$-Glu(OtBu)-PTX

B

FITC

FITC-Glu(OtBu)-PTX

-NH$_2$-Glu(COOH)-PTX

ICG02-Glu(OtBu)-PTX
Fig. 1. Characterization of intermediate compounds. (A) \(-\text{NH}_2\)-Glu(OtBu)-PTX: MS (ESI, m/z): 1283.4([M+Na]⁺). (B) The fluorescence of FITC can be observed from the TLC of purified FITC-Glu(OtBu)-PTX using TLC imaging system, and the fluorescence of ICG02 can be observed from TLC of purified ICG02-Glu(OtBu)-PTX using NIR imaging system. (C) FITC-Glu(COOH)-PTX: MS(ESI,m/z): 1389.42([M+H]⁺).
Fig. 2. (A) Mean fluorescence emission intensities of Tf-Glu-PTX-FITC or FTIC-Glu-PTX from different cells: 293T, MDA-MB-231, MCF-7, and A549 cell. (B) Fluorescence intensity analysis of MDA-MB-231/PS and MDA-MB-231/PR cells after incubation with Tf-Glu-PTX-FITC or FTIC-Glu-PTX.
Table 1: The IC\textsubscript{50} of PTX and Tf-Glu-PTX from different cell lines.

<table>
<thead>
<tr>
<th>Drug</th>
<th>MDA-MB-231</th>
<th>MCF-7</th>
<th>A549</th>
<th>293T</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTX</td>
<td>62.67</td>
<td>64.46</td>
<td>65.91</td>
<td>28.19</td>
</tr>
<tr>
<td>Tf-Glu-PTX</td>
<td>18.83</td>
<td>21.49</td>
<td>24.12</td>
<td>42.18</td>
</tr>
</tbody>
</table>